PMID- 32329194 OWN - NLM STAT- MEDLINE DCOM- 20210604 LR - 20221207 IS - 1753-0407 (Electronic) IS - 1753-0407 (Linking) VI - 12 IP - 9 DP - 2020 Sep TI - Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). PG - 668-676 LID - 10.1111/1753-0407.13046 [doi] AB - BACKGROUND: The efficacy of basal insulin (BI) for adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) has been well documented by randomized clinical trials. This post hoc analysis of the Observational Registry of Basal Insulin Treatment (ORBIT) study was performed to explore the 6-month dose of BI used in insulin-naive T2DM patients achieving HbA1c target (<7%) and determine the patient characteristics that affect the 6-month dose of BI in the setting of real-world clinics in China. METHODS: This multicenter observational registry screened 19 894 adult T2DM patients with inadequately controlled hyperglycemia and treated with oral antidiabetic drugs (OADs) in China. Of these patients, 5191 who continued to receive BI after 6 months and achieved HbA1c target were analyzed. Patient characteristics including age, body weight, fasting plasma glucose (FPG), use of OADs, insulin (type and dose), and glycemic control were recorded at baseline and 6-month follow-ups. RESULTS: The 6-month dose of BI needed for effective glycemic control was 0.20 +/- 0.08 U/kg/day. High body mass index, high FPG, young age, longer duration of diabetes or OAD treatment, a greater number of OADs at baseline, and allocation to detemir and glargine were significant independent predictors for high dose of BI at 6 months. CONCLUSIONS: This post hoc analysis of the ORBIT registry provides key information on the 6-month dose of BI needed for effective glycemic control in Chinese T2DM patients. Furthermore, it identified crucial patient characteristics that are significant determinants of the dose of BI in a real-world setting. CI - (c) 2020 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd. FAU - Gao, Leili AU - Gao L AUID- ORCID: 0000-0003-4928-9418 AD - Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. FAU - Zhang, Puhong AU - Zhang P AD - Diabetes Program, The George Institute for Global Health at Peking University Health Science Center, Beijing, China. FAU - Weng, Jianping AU - Weng J AUID- ORCID: 0000-0003-2705-196X AD - Department of Endocrinology, The First Affiliated Hospital, Division of life sciences and medicine, University of Science and Technology of China, Hefei, China. FAU - Lu, Juming AU - Lu J AD - Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing, China. FAU - Guo, Xiaohui AU - Guo X AD - Department of Endocrinology, Peking University First Hospital, Beijing, China. FAU - Jia, Weiping AU - Jia W AD - Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Yang, Wenying AU - Yang W AD - Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China. FAU - Zou, Dajin AU - Zou D AD - Department of Endocrinology, The Second Military Medical University, Shanghai, China. FAU - Zhou, Zhiguang AU - Zhou Z AD - Department of Endocrinology, Xiangya Second Hospital, Changsha, China. FAU - Pan, Changyu AU - Pan C AD - Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing, China. FAU - Gao, Yan AU - Gao Y AD - Department of Endocrinology, Peking University First Hospital, Beijing, China. FAU - Li, Xian AU - Li X AD - Diabetes Program, The George Institute for Global Health at Peking University Health Science Center, Beijing, China. FAU - Zhu, Dongshan AU - Zhu D AD - Diabetes Program, The George Institute for Global Health at Peking University Health Science Center, Beijing, China. FAU - Wu, Yangfeng AU - Wu Y AD - Diabetes Program, The George Institute for Global Health at Peking University Health Science Center, Beijing, China. FAU - Garg, Satish K AU - Garg SK AD - Barbara Davis Center for Diabetes, University of Colorado Denver, Colorado, Aurora, USA. FAU - Ji, Linong AU - Ji L AUID- ORCID: 0000-0002-3262-2168 AD - Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. LA - eng GR - The study was funded by Sanofi-Aventis(Shanghai, China). The funders had no role in the design and conduct of the study, nor the decision to submit the manuscript for publication./ PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20200529 PL - Australia TA - J Diabetes JT - Journal of diabetes JID - 101504326 RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin A) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) RN - 0 (hemoglobin A1c protein, human) SB - IM MH - Biomarkers/*analysis MH - Blood Glucose/analysis MH - China/epidemiology MH - Diabetes Mellitus, Type 2/*drug therapy/epidemiology MH - Dose-Response Relationship, Drug MH - Female MH - Follow-Up Studies MH - Glycated Hemoglobin/*analysis MH - Humans MH - Hypoglycemic Agents/*therapeutic use MH - Insulin/*therapeutic use MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Registries/*statistics & numerical data OTO - NOTNLM OT - 6-month dose OT - 6个月时的剂量 OT - China OT - HbA1c OT - basal insulin OT - diabetes OT - 中国 OT - 基础胰岛素 OT - 糖化血红蛋白 OT - 糖尿病 EDAT- 2020/04/25 06:00 MHDA- 2021/06/05 06:00 CRDT- 2020/04/25 06:00 PHST- 2019/07/28 00:00 [received] PHST- 2020/04/16 00:00 [revised] PHST- 2020/04/19 00:00 [accepted] PHST- 2020/04/25 06:00 [pubmed] PHST- 2021/06/05 06:00 [medline] PHST- 2020/04/25 06:00 [entrez] AID - 10.1111/1753-0407.13046 [doi] PST - ppublish SO - J Diabetes. 2020 Sep;12(9):668-676. doi: 10.1111/1753-0407.13046. Epub 2020 May 29.